Literature DB >> 6139020

Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies.

D J Wilson, J D Wallin, N D Vlachakis, E D Freis, D G Vidt, E L Michelson, H G Langford, W Flamenbaum, M P Poland.   

Abstract

The antihypertensive effects of intravenous labetalol were evaluated in 59 patients with hypertensive crises or severe hypertension in need of rapid lowering of blood pressure in a multicenter study. Patients appearing with a supine diastolic blood pressure 125 mm Hg or greater, or a supine systolic blood pressure of more than 200 mm Hg received an initial mini-bolus injection (20 mg) of labetalol. This was followed by repeated incremental doses of 20 to 80 mg given at 10 minute intervals to achieve a supine diastolic blood pressure of less than 95 mm Hg or decrease 30 mm Hg or greater, or a satisfactory decrease in systolic blood pressure. Patients were stratified into those who had taken antihypertensive medication within 24 hours and those who had not. The initial mini-bolus injection caused rapid but not abrupt reduction in blood pressure; the baseline mean blood pressure decreased 23/14 mm Hg. Further injections were needed in the majority of patients (mean: 197 mg). The blood pressure reduction after the last dose of labetalol was 55/33 mm Hg. In pretreated patients and in those who had no medication for 24 hours prior to the intravenous labetalol, the response was similar. Heart rate decreased 10 beats per minute in the total population. In patients pretreated with beta-adrenergic blockers, blood pressure response was similar to that in the total group (59/35 versus 55/33 mm Hg), but heart rate remained essentially unchanged. The dose required to achieve the therapeutic effect was less in pretreated patients than in untreated patients, but the duration of action was shorter. No serious adverse effects were encountered even in patients with concomitant diagnoses of acute left ventricular failure, myocardial infarction, stable congestive heart failure, atrial fibrillation, angina pectoris, acute stroke, transient ischemic attack or encephalopathy. Labetalol is a safe and effective treatment for a rapid blood pressure reduction in hypertensive emergencies.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6139020     DOI: 10.1016/0002-9343(83)90141-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

2.  Pheochromocytoma.

Authors:  C Reuse; J L Vincent; C Matos; M de Rood; J Unger
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

Review 3.  Hypertensive emergencies and urgencies: definition, recognition, and management.

Authors:  J B Reuler; G J Magarian
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

Review 4.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 5.  Comparative tolerability profile of hypertensive crisis treatments.

Authors:  E Grossman; A N Ironi; F H Messerli
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

6.  A comparison of esmolol and labetalol for the treatment of perioperative hypertension in geriatric ambulatory surgical patients.

Authors:  P P Singh; I Dimich; I Sampson; N Sonnenklar
Journal:  Can J Anaesth       Date:  1992-07       Impact factor: 5.063

Review 7.  Current management of hypertensive emergencies.

Authors:  J Y Garcia; D G Vidt
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

8.  [Effectiveness and hemodynamic mechanism of action of blood pressure lowering by intravenous labetalol in patients with a critical increase in blood pressure].

Authors:  H P Schuster; B Ehlers; K F Bodmann; F Köhler
Journal:  Klin Wochenschr       Date:  1989-07-17

Review 9.  Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.

Authors:  K Miller
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

10.  Hypertensive crisis with optic disc edema and cerebral white matter lesions.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.